Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KEPPRA XR vs MILONTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.
Increases seizure threshold by inhibiting voltage-gated sodium channels and enhancing GABAergic inhibition.
Adjunctive therapy for partial-onset seizures in adults and children aged ≥4 years,Adjunctive therapy for myoclonic seizures in adults and adolescents aged ≥12 years with juvenile myoclonic epilepsy,Adjunctive therapy for primary generalized tonic-clonic seizures in adults and children aged ≥6 years with idiopathic generalized epilepsy
Adjunctive therapy in the treatment of absence seizures
1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.
Oral, 500 mg twice daily; may increase by 250-500 mg/day every 2-3 days; usual dose 1-2 g/day in 2-3 divided doses; maximum 3 g/day.
7.1 ± 1.1 hours in adults; 10–11 hours in elderly; prolonged in renal impairment (up to 25 hours in severe renal failure).
Terminal elimination half-life is 6–8 hours in adults, longer in children (8–12 hours) and elderly (10–14 hours); clinical context: requires multiple daily dosing to maintain therapeutic levels.
Metabolized primarily by hydrolysis of the acetamide group via enzymatic hydrolysis (not CYP450 dependent); forms inactive metabolite (UCB L057); ~24% of dose undergoes oxidative metabolism.
Hepatic via glucuronidation and oxidation; CYP450 involvement minimal.
Renal: 66% as unchanged drug; 27% as inactive metabolite (uch L057); biliary/fecal: negligible (<1%).
Primarily hepatic metabolism and renal excretion; approximately 60% of a dose is excreted in urine as conjugated metabolite (phensuximide glucuronide), with 15% as unchanged drug; 20% eliminated in feces.
<10%; binding to albumin (not extensive).
Negligible; less than 1% bound to plasma proteins, primarily albumin.
0.5–0.7 L/kg; suggests distribution into total body water.
0.7–0.9 L/kg; clinical meaning: distribution consistent with total body water, indicating minimal tissue binding.
100% for oral tablet (immediate-release); 100% for extended-release (relative to immediate-release).
Oral: nearly 100% (well absorbed from GI tract); no parenteral formulation available.
For Cr Cl > 80 m L/min: 1500 mg once daily; Cr Cl 50-80 m L/min: 1000 mg once daily; Cr Cl 30-49 m L/min: 500 mg once daily; Cr Cl < 30 m L/min: 250 mg once daily. ESRD on dialysis: 500 mg once daily with 250 mg supplemental dose post-dialysis.
Cr Cl < 50 m L/min: avoid use. No data for milder impairment.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), reduce dose by 50%.
No specific adjustment recommended; use with caution in severe hepatic impairment.
For children ≥12 years (≥40 kg): 1500 mg orally once daily. Not FDA-approved for <12 years; use immediate-release formulation for pediatric patients <12 years: starting dose 10 mg/kg twice daily, titrated to 30 mg/kg twice daily.
Children 7-12 years: 300 mg orally twice daily initially; increase by 300 mg/day every 2-3 days; usual 600-1200 mg/day in 2-3 divided doses. Infants and children under 7: not recommended.
Elderly patients often have reduced creatinine clearance; dose should be adjusted based on renal function. Monitor for drowsiness, dizziness, and ataxia. Start at lower end of dosing range and titrate cautiously.
Start at lower end of dosing range; monitor for sedation and falls; adjust based on renal function.
No FDA black box warning.
No FDA black box warning.
Behavioral abnormalities including psychosis, aggression, hostility, irritability, and suicidal ideation/behavior,Somnolence and fatigue,Serious dermatologic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic abnormalities (decreased red blood cell, white blood cell, and platelet counts),Increased blood pressure in pediatric patients,Withdrawal seizures upon abrupt discontinuation
May cause drowsiness, dizziness; use caution with other CNS depressants; monitor for blood dyscrasias; withdraw gradually to avoid precipitating seizures.
Hypersensitivity to levetiracetam or any component of the formulation
Hypersensitivity to succinimides; history of porphyria; concurrent use with MAOIs (relative).
No significant food interactions. Grapefruit juice does not affect levetiracetam. Avoid alcohol as it may exacerbate CNS depression.
No specific food interactions known. Maintain consistent alcohol intake; avoid excessive alcohol as it may lower seizure threshold.
Pregnancy Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) with antiepileptic drug polytherapy; monotherapy association unclear but may be dose-dependent. Second/third trimester: Risk of fetal growth restriction, hemorrhagic disease of newborn (vitamin K deficiency due to enzyme induction). Perinatal: Neonatal withdrawal syndrome, sedation, and coagulopathy.
Phensuximide (Milontin) is an older succinimide anticonvulsant. Human data are limited, but animal studies have shown teratogenic effects. The risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies, is considered increased, especially with first-trimester exposure. Its use in pregnancy is generally avoided unless no safer alternative exists. The risk is highest during the first trimester (organogenesis). Second and third trimester exposure may be associated with growth restriction and neurodevelopmental effects, but data are sparse.
Levetiracetam is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Relative infant dose is low (2–7% of weight-adjusted maternal dose). Limited data suggest no adverse effects in breastfed infants, but monitor for drowsiness, poor feeding. Benefit likely outweighs risk in most cases.
Phensuximide is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 0.8. Relative infant dose is estimated at 5-10% of the maternal weight-adjusted dose, which is below the 10% safety threshold; however, individual variability exists. Monitor the infant for drowsiness, poor feeding, and potential hypersensitivity reactions. Breastfeeding is generally considered acceptable with caution, especially if maternal therapy is necessary.
Increased clearance of levetiracetam during pregnancy, particularly in the second and third trimesters (up to 50–60% higher). Dose adjustments may be required to maintain therapeutic trough levels (target 12–46 µg/m L). Consider therapeutic drug monitoring every 1–3 months and after delivery, with gradual dose reduction to pre-pregnancy levels within 1–2 weeks postpartum.
Pregnancy can increase the clearance of succinimides, potentially reducing serum concentrations. Monitor serum levels frequently (every 4-6 weeks) and adjust dose to maintain therapeutic levels (40-100 mcg/m L) for seizure control. Dose increases may be needed, particularly in the second and third trimesters. Postpartum, doses may need to be reduced to pre-pregnancy levels to avoid toxicity.
Keppra XR (levetiracetam extended-release) is dosed once daily due to its prolonged absorption profile. Therapeutic drug monitoring is not routinely required because of its predictable pharmacokinetics and wide therapeutic index. Adjust dose in renal impairment (Cr Cl < 80 m L/min) using ideal body weight; supplement dose after hemodialysis. May cause somnolence, dizziness, and behavioral changes (e.g., aggression, psychosis) especially in pediatric and elderly patients. Stevens-Johnson syndrome and angioedema are rare but serious adverse effects. Sudden discontinuation may precipitate withdrawal seizures; taper over at least 2 weeks.
Milontin (phensuximide) is a succinimide anticonvulsant primarily used for absence seizures. It is a second-line agent after ethosuximide due to higher risk of adverse effects. Monitor for bone marrow suppression, including agranulocytosis and pancytopenia; obtain baseline and periodic CBCs. Hepatitis and nephrosis have been reported; assess liver and renal function periodically. Psychotic episodes may occur, especially in patients with prior psychiatric history. Taper gradually to avoid withdrawal seizures.
Take exactly as prescribed once daily with or without food, at the same time each day.,Swallow tablet whole; do not crush, chew, or break.,Do not drive or operate heavy machinery until you know how this medicine affects you.,Contact your doctor immediately if you experience skin rash, blistering, swelling of face/lips, or difficulty breathing.,Inform your doctor of any history of depression, mood swings, aggressive behavior, or suicidal thoughts.,Report any worsening of seizures or new types of seizures.,If you are on dialysis, take the recommended supplement dose after each session.,Do not stop taking this medicine suddenly as it may cause withdrawal seizures.,Avoid alcohol while taking Keppra XR; it may increase drowsiness and dizziness.
Take exactly as prescribed; do not stop suddenly as this can cause breakthrough seizures.,Report any signs of infection (fever, sore throat, mouth sores) immediately due to risk of blood disorders.,Notify your doctor if you experience unusual bleeding or bruising, dark urine, or jaundice.,Avoid driving or operating heavy machinery until you know how this medication affects you; it may cause drowsiness or dizziness.,Regular blood tests are required to monitor for side effects.,Use effective contraception if of childbearing age; discuss pregnancy plans with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KEPPRA XR vs MILONTIN, answered by our medical review team.
KEPPRA XR is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.. MILONTIN is a Antiepileptic that works by Increases seizure threshold by inhibiting voltage-gated sodium channels and enhancing GABAergic inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KEPPRA XR and MILONTIN depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KEPPRA XR is: 1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.. The standard adult dose of MILONTIN is: Oral, 500 mg twice daily; may increase by 250-500 mg/day every 2-3 days; usual dose 1-2 g/day in 2-3 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KEPPRA XR and MILONTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KEPPRA XR is classified as Category C. Pregnancy Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) with antiepileptic drug polytherapy; monotherapy a. MILONTIN is classified as Category C. Phensuximide (Milontin) is an older succinimide anticonvulsant. Human data are limited, but animal studies have shown teratogenic effects. The risk of major congenital malformation. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.